Home > Journals > Minerva Pediatrica > Past Issues > Minerva Pediatrica 2018 February;70(1) > Minerva Pediatrica 2018 February;70(1):59-66

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

REVIEW   

Minerva Pediatrica 2018 February;70(1):59-66

DOI: 10.23736/S0026-4946.17.05147-7

Copyright © 2017 EDIZIONI MINERVA MEDICA

language: English

Safety of HPV vaccines in the age of nonavalent vaccination

Filippo QUATTRONE , Alice CANALE, Elisa FILIPPETTI, Alberto TULIPANI, Andrea PORRETTA, Pier L. LOPALCO

Unit of Hygiene and Epidemiology, Department of Translational Research, New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy


PDF


To date three vaccines against human papilloma virus (HPV) have been licensed: a bivalent, a quadrivalent and, in 2014, a nonavalent vaccine. Despite the early implementation of national vaccination programs, in the majority of developed countries coverage rates remain unsatisfactory. Rumors about vaccine safety have been one of the principal obstacles for the acceptance of HPV vaccination by the public. It is therefore of primary importance to provide the public with clear and up-to-date information about HPV vaccination safety. To this aim, in this narrative review we will summarize safety data from pre and postlicensure studies for the three HPV vaccines available with a focus on the safety profile of the new nonavalent vaccine.


KEY WORDS: Papillomavirus vaccines - Vaccines - Review

top of page